cd11b hcd45 Search Results


human cd45 cd33 cd11b cells  (Miltenyi Biotec)
95
Miltenyi Biotec human cd45 cd33 cd11b cells
a Diagnostic bone marrow aspirates from breast (BrCa, n = 19) or prostate (PC, n = 27) cancer patients (M0- or M1-stage of disease) were either <t>CD45-depleted,</t> enriched for EpCAM, or cultured under sphere conditions. Resulting spheres, CD45-depleted, or EpCAM-enriched BM cells were injected intra-venously (i.v.), intra-femorally (i.f.), sub-cutaneously (s.c.), sub-renally (s.r.), or into the mammary fat pad (mfp) of NOD-scid or NOD-scidIL2Rγ-/- mice. Mice with sub-cutaneous or mammary fat pad injections were palpated weekly. All other mice were observed until signs of illness or were sacrificed after 9 months. Injection routes that led to xenograft formation are highlighted in red. b Immunohistochemistry for estrogen-receptor (ER), progesterone-receptor (PR), prostate-specific antigen (PSA), Ki-67, or H & E staining of M1-DCC-derived xenografts is shown. c Human EpCAM- or cytokeratin 8/18/19-expressing DCCs were detected in the BM of 4/42 mice transplanted with M0-stage patient samples. DCCs from two of the four mice were isolated and their human origin was verified by a PCR specific for human KRT19. Pure mouse or human DNA was used as control. 1, 2 = cytokeratin 8/18/19-positive DCCs; N = cytokeratin 8/18/19-negative BM-cell, P = pool of BM-cells of recipient mouse; m = mouse positive control; h = human positive control, c = non-template control. d Single cell CNA analysis of the EpCAM-expressing DCC isolated at 4 weeks after injection from NSG BM ( c ) and a human hematopoietic cell as control. Red or blue indicate gain or loss of chromosomal regions.
Human Cd45 Cd33 Cd11b Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd45 cd33 cd11b cells/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
human cd45 cd33 cd11b cells - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
cd11b hcd45  (Miltenyi Biotec)
99
Miltenyi Biotec cd11b hcd45
a Diagnostic bone marrow aspirates from breast (BrCa, n = 19) or prostate (PC, n = 27) cancer patients (M0- or M1-stage of disease) were either <t>CD45-depleted,</t> enriched for EpCAM, or cultured under sphere conditions. Resulting spheres, CD45-depleted, or EpCAM-enriched BM cells were injected intra-venously (i.v.), intra-femorally (i.f.), sub-cutaneously (s.c.), sub-renally (s.r.), or into the mammary fat pad (mfp) of NOD-scid or NOD-scidIL2Rγ-/- mice. Mice with sub-cutaneous or mammary fat pad injections were palpated weekly. All other mice were observed until signs of illness or were sacrificed after 9 months. Injection routes that led to xenograft formation are highlighted in red. b Immunohistochemistry for estrogen-receptor (ER), progesterone-receptor (PR), prostate-specific antigen (PSA), Ki-67, or H & E staining of M1-DCC-derived xenografts is shown. c Human EpCAM- or cytokeratin 8/18/19-expressing DCCs were detected in the BM of 4/42 mice transplanted with M0-stage patient samples. DCCs from two of the four mice were isolated and their human origin was verified by a PCR specific for human KRT19. Pure mouse or human DNA was used as control. 1, 2 = cytokeratin 8/18/19-positive DCCs; N = cytokeratin 8/18/19-negative BM-cell, P = pool of BM-cells of recipient mouse; m = mouse positive control; h = human positive control, c = non-template control. d Single cell CNA analysis of the EpCAM-expressing DCC isolated at 4 weeks after injection from NSG BM ( c ) and a human hematopoietic cell as control. Red or blue indicate gain or loss of chromosomal regions.
Cd11b Hcd45, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd11b hcd45/product/Miltenyi Biotec
Average 99 stars, based on 1 article reviews
cd11b hcd45 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
treatment facs bioxcell anti human cd14 m5e2 facs biolegend anti human cd45 hi30 facs biolegend  (Bio X Cell)
94
Bio X Cell treatment facs bioxcell anti human cd14 m5e2 facs biolegend anti human cd45 hi30 facs biolegend
a Diagnostic bone marrow aspirates from breast (BrCa, n = 19) or prostate (PC, n = 27) cancer patients (M0- or M1-stage of disease) were either <t>CD45-depleted,</t> enriched for EpCAM, or cultured under sphere conditions. Resulting spheres, CD45-depleted, or EpCAM-enriched BM cells were injected intra-venously (i.v.), intra-femorally (i.f.), sub-cutaneously (s.c.), sub-renally (s.r.), or into the mammary fat pad (mfp) of NOD-scid or NOD-scidIL2Rγ-/- mice. Mice with sub-cutaneous or mammary fat pad injections were palpated weekly. All other mice were observed until signs of illness or were sacrificed after 9 months. Injection routes that led to xenograft formation are highlighted in red. b Immunohistochemistry for estrogen-receptor (ER), progesterone-receptor (PR), prostate-specific antigen (PSA), Ki-67, or H & E staining of M1-DCC-derived xenografts is shown. c Human EpCAM- or cytokeratin 8/18/19-expressing DCCs were detected in the BM of 4/42 mice transplanted with M0-stage patient samples. DCCs from two of the four mice were isolated and their human origin was verified by a PCR specific for human KRT19. Pure mouse or human DNA was used as control. 1, 2 = cytokeratin 8/18/19-positive DCCs; N = cytokeratin 8/18/19-negative BM-cell, P = pool of BM-cells of recipient mouse; m = mouse positive control; h = human positive control, c = non-template control. d Single cell CNA analysis of the EpCAM-expressing DCC isolated at 4 weeks after injection from NSG BM ( c ) and a human hematopoietic cell as control. Red or blue indicate gain or loss of chromosomal regions.
Treatment Facs Bioxcell Anti Human Cd14 M5e2 Facs Biolegend Anti Human Cd45 Hi30 Facs Biolegend, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/treatment facs bioxcell anti human cd14 m5e2 facs biolegend anti human cd45 hi30 facs biolegend/product/Bio X Cell
Average 94 stars, based on 1 article reviews
treatment facs bioxcell anti human cd14 m5e2 facs biolegend anti human cd45 hi30 facs biolegend - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
mouse anti-human cd45 antibody conjugated with apc  (Galectin Therapeutics)
90
Galectin Therapeutics mouse anti-human cd45 antibody conjugated with apc
a Diagnostic bone marrow aspirates from breast (BrCa, n = 19) or prostate (PC, n = 27) cancer patients (M0- or M1-stage of disease) were either <t>CD45-depleted,</t> enriched for EpCAM, or cultured under sphere conditions. Resulting spheres, CD45-depleted, or EpCAM-enriched BM cells were injected intra-venously (i.v.), intra-femorally (i.f.), sub-cutaneously (s.c.), sub-renally (s.r.), or into the mammary fat pad (mfp) of NOD-scid or NOD-scidIL2Rγ-/- mice. Mice with sub-cutaneous or mammary fat pad injections were palpated weekly. All other mice were observed until signs of illness or were sacrificed after 9 months. Injection routes that led to xenograft formation are highlighted in red. b Immunohistochemistry for estrogen-receptor (ER), progesterone-receptor (PR), prostate-specific antigen (PSA), Ki-67, or H & E staining of M1-DCC-derived xenografts is shown. c Human EpCAM- or cytokeratin 8/18/19-expressing DCCs were detected in the BM of 4/42 mice transplanted with M0-stage patient samples. DCCs from two of the four mice were isolated and their human origin was verified by a PCR specific for human KRT19. Pure mouse or human DNA was used as control. 1, 2 = cytokeratin 8/18/19-positive DCCs; N = cytokeratin 8/18/19-negative BM-cell, P = pool of BM-cells of recipient mouse; m = mouse positive control; h = human positive control, c = non-template control. d Single cell CNA analysis of the EpCAM-expressing DCC isolated at 4 weeks after injection from NSG BM ( c ) and a human hematopoietic cell as control. Red or blue indicate gain or loss of chromosomal regions.
Mouse Anti Human Cd45 Antibody Conjugated With Apc, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-human cd45 antibody conjugated with apc/product/Galectin Therapeutics
Average 90 stars, based on 1 article reviews
mouse anti-human cd45 antibody conjugated with apc - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


a Diagnostic bone marrow aspirates from breast (BrCa, n = 19) or prostate (PC, n = 27) cancer patients (M0- or M1-stage of disease) were either CD45-depleted, enriched for EpCAM, or cultured under sphere conditions. Resulting spheres, CD45-depleted, or EpCAM-enriched BM cells were injected intra-venously (i.v.), intra-femorally (i.f.), sub-cutaneously (s.c.), sub-renally (s.r.), or into the mammary fat pad (mfp) of NOD-scid or NOD-scidIL2Rγ-/- mice. Mice with sub-cutaneous or mammary fat pad injections were palpated weekly. All other mice were observed until signs of illness or were sacrificed after 9 months. Injection routes that led to xenograft formation are highlighted in red. b Immunohistochemistry for estrogen-receptor (ER), progesterone-receptor (PR), prostate-specific antigen (PSA), Ki-67, or H & E staining of M1-DCC-derived xenografts is shown. c Human EpCAM- or cytokeratin 8/18/19-expressing DCCs were detected in the BM of 4/42 mice transplanted with M0-stage patient samples. DCCs from two of the four mice were isolated and their human origin was verified by a PCR specific for human KRT19. Pure mouse or human DNA was used as control. 1, 2 = cytokeratin 8/18/19-positive DCCs; N = cytokeratin 8/18/19-negative BM-cell, P = pool of BM-cells of recipient mouse; m = mouse positive control; h = human positive control, c = non-template control. d Single cell CNA analysis of the EpCAM-expressing DCC isolated at 4 weeks after injection from NSG BM ( c ) and a human hematopoietic cell as control. Red or blue indicate gain or loss of chromosomal regions.

Journal: Nature Communications

Article Title: Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

doi: 10.1038/s41467-020-18701-4

Figure Lengend Snippet: a Diagnostic bone marrow aspirates from breast (BrCa, n = 19) or prostate (PC, n = 27) cancer patients (M0- or M1-stage of disease) were either CD45-depleted, enriched for EpCAM, or cultured under sphere conditions. Resulting spheres, CD45-depleted, or EpCAM-enriched BM cells were injected intra-venously (i.v.), intra-femorally (i.f.), sub-cutaneously (s.c.), sub-renally (s.r.), or into the mammary fat pad (mfp) of NOD-scid or NOD-scidIL2Rγ-/- mice. Mice with sub-cutaneous or mammary fat pad injections were palpated weekly. All other mice were observed until signs of illness or were sacrificed after 9 months. Injection routes that led to xenograft formation are highlighted in red. b Immunohistochemistry for estrogen-receptor (ER), progesterone-receptor (PR), prostate-specific antigen (PSA), Ki-67, or H & E staining of M1-DCC-derived xenografts is shown. c Human EpCAM- or cytokeratin 8/18/19-expressing DCCs were detected in the BM of 4/42 mice transplanted with M0-stage patient samples. DCCs from two of the four mice were isolated and their human origin was verified by a PCR specific for human KRT19. Pure mouse or human DNA was used as control. 1, 2 = cytokeratin 8/18/19-positive DCCs; N = cytokeratin 8/18/19-negative BM-cell, P = pool of BM-cells of recipient mouse; m = mouse positive control; h = human positive control, c = non-template control. d Single cell CNA analysis of the EpCAM-expressing DCC isolated at 4 weeks after injection from NSG BM ( c ) and a human hematopoietic cell as control. Red or blue indicate gain or loss of chromosomal regions.

Article Snippet: For xenotransplantations of DCCs, mononuclear cells from BM aspirates of nonmetastasized or metastasized breast or prostate cancer patients were enriched for human EpCAM or depleted of human CD45 + CD33 + CD11b + cells and erythrocytes using a mix of CD45, CD33, CD11b, and glycophorin A microbeads according to the manufacturer’s instructions (Miltenyi Biotec, Germany).

Techniques: Diagnostic Assay, Cell Culture, Injection, Immunohistochemistry, Staining, Derivative Assay, Expressing, Isolation, Control, Positive Control

a Fold change in sphere numbers of pre-malignant (MCF 10A) and tumorigenic cell lines (MCF-7, MDA-MB-231) without (MCF 10A parental, n = 8; MDA-MB-231, n = 6) or with mutational activation of PIK3CA (MCF 10A PIK3CAE545K/+, n = 7; MCF-7, n = 6) cultured in the presence or absence of HIL6. Note that MCF 10A PIK3CAE545K/+ cells are isogenic to MCF 10A parental; n.s. = non-significant. b Western blot analyses showing phosphorylation of STAT3Tyr705, AKTSer475 and ERK1/2Thr202/Tyr204 in MCF 10A or MCF 10A PIK3CAE545K/+ cells cultured without or with HIL6 for the indicated time. For quantification, the signal of the phosphorylated protein and total protein was normalized to α-tubulin, then the ratio of phosphorylated to total protein was calculated. The graphs show the fold change in signal ratio over time relative to the control (unstimulated MCF 10A wt = 1). c Sphere numbers of the isogenic cells MCF 10A parental ( n = 8) and MCF 10A PIK3CAE545K/+ ( n = 7) cultured in the absence of HIL6. d Cytokeratin 8/18/19+ DCCs from BM of non-metastasized (M0-stage) HR-positive breast cancer patients and CD45-/EpCAM+/cytokeratin 8/18/19+ CTCs isolated from peripheral blood of metastasized (M1-stage) HR-positive breast cancer patients were sequenced for hotspot-mutations in PIK3CA (Exon 9: E545K, E542K; Exon 20: H1047R, H1047L, M1043I). P values in a , c two-sided Student’s test; d two-sided Fisher’s exact test. All error bars correspond to standard deviation (Mean ± SD).

Journal: Nature Communications

Article Title: Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

doi: 10.1038/s41467-020-18701-4

Figure Lengend Snippet: a Fold change in sphere numbers of pre-malignant (MCF 10A) and tumorigenic cell lines (MCF-7, MDA-MB-231) without (MCF 10A parental, n = 8; MDA-MB-231, n = 6) or with mutational activation of PIK3CA (MCF 10A PIK3CAE545K/+, n = 7; MCF-7, n = 6) cultured in the presence or absence of HIL6. Note that MCF 10A PIK3CAE545K/+ cells are isogenic to MCF 10A parental; n.s. = non-significant. b Western blot analyses showing phosphorylation of STAT3Tyr705, AKTSer475 and ERK1/2Thr202/Tyr204 in MCF 10A or MCF 10A PIK3CAE545K/+ cells cultured without or with HIL6 for the indicated time. For quantification, the signal of the phosphorylated protein and total protein was normalized to α-tubulin, then the ratio of phosphorylated to total protein was calculated. The graphs show the fold change in signal ratio over time relative to the control (unstimulated MCF 10A wt = 1). c Sphere numbers of the isogenic cells MCF 10A parental ( n = 8) and MCF 10A PIK3CAE545K/+ ( n = 7) cultured in the absence of HIL6. d Cytokeratin 8/18/19+ DCCs from BM of non-metastasized (M0-stage) HR-positive breast cancer patients and CD45-/EpCAM+/cytokeratin 8/18/19+ CTCs isolated from peripheral blood of metastasized (M1-stage) HR-positive breast cancer patients were sequenced for hotspot-mutations in PIK3CA (Exon 9: E545K, E542K; Exon 20: H1047R, H1047L, M1043I). P values in a , c two-sided Student’s test; d two-sided Fisher’s exact test. All error bars correspond to standard deviation (Mean ± SD).

Article Snippet: For xenotransplantations of DCCs, mononuclear cells from BM aspirates of nonmetastasized or metastasized breast or prostate cancer patients were enriched for human EpCAM or depleted of human CD45 + CD33 + CD11b + cells and erythrocytes using a mix of CD45, CD33, CD11b, and glycophorin A microbeads according to the manufacturer’s instructions (Miltenyi Biotec, Germany).

Techniques: Activation Assay, Cell Culture, Western Blot, Phospho-proteomics, Control, Isolation, Standard Deviation